Sino Biopharmaceutical Limited said its subsidiary Chia Tai Tianqing Pharmaceutical Group has entered into an exclusive license agreement with a wholly owned unit of Sanofi for the global development, manufacturing and commercialization of its JAK/ROCK inhibitor rovadicitinib. Under the deal, Sino Biopharm is eligible to receive a US$135 million upfront payment, up to US$1.395 billion in potential development, regulatory and sales milestones, and tiered royalties based on annual net sales, subject to customary closing conditions and regulatory clearances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260304-12039206), on March 03, 2026, and is solely responsible for the information contained therein.